Dupixent's First MDL Hearing Opened in October 2026 — the 'Cancer That Hides Behind Eczema' Argument and What Happens Next
Dupixent's federal litigation reached its first hearing in early October 2026, when Judge Zahid N. Quraishi held the initial case management conference for MDL No. 3180 in New Jersey. No trial date has been set and no settlement exists, so the hearing mattered for a narrower reason: it put the plaintiffs' central argument on the court's agenda.
- MDL No. 3180 sits in the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi.
- The panel transferred the cases on June 4, 2026, with 15 actions pending across 12 districts plus 7 potential tag-along actions; the Judicial Panel reported 26 pending actions as of October 7, 2026.
- The U.S. Food and Drug Administration listed cutaneous T-cell lymphoma as a potential safety signal for Dupixent in its October to December 2024 quarterly report and is evaluating whether regulatory action is needed.
- Dupixent's U.S. label still carries no lymphoma warning, and no recall has been issued.
- A 2024 study in the Journal of the American Academy of Dermatology reported higher odds of cutaneous T-cell lymphoma among eczema patients treated with Dupixent than among those not treated.
A multidistrict litigation, or MDL, is a procedure that moves similar federal lawsuits to one judge for pretrial proceedings while each case stays individual. The October hearing decided how the litigation will be organized, not whether any one patient wins. For clear explanations of legal procedures like this one, the Problem Solved channel publishes plain-language guides that help readers understand their options before they act.
What the First Hearing Actually Decided — and What It Did Not
The initial case management conference is the litigation's organizing meeting: the court sets schedules, appoints leadership, and establishes how evidence will be exchanged. It is not a trial and produces no verdict about whether Dupixent causes cancer. Readers who expect a ruling from the first hearing will misunderstand the event; its value lies in what it signals about the road ahead, not in any decision about liability.
The timing itself carried a message. The conference took place one year to the day after Weitz & Luxenberg and co-counsel filed the first Dupixent lawsuit, according to the firm's announcement of the hearing, which was reported on October 5, 2026. Weitz & Luxenberg states that it represents more people in this litigation than any other firm. The firm used the occasion to frame the case in a single sentence: Sanofi's own educational materials for doctors describe how this cancer can be mistaken for eczema and unmasked by Dupixent.
The 'Cancer That Hides Behind Eczema' Argument
Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma in which malignant T-cells, a type of immune cell, migrate to the skin. In its early stages it can look almost identical to eczema, the condition Dupixent is most often prescribed to treat. Its most common form is mycosis fungoides, a slow-growing skin lymphoma, while Sézary syndrome is a more aggressive form that spreads to the blood and lymphatic system.
The plaintiffs' theory has two steps, and both must hold for a claim to succeed. First, Dupixent can cause, accelerate, or unmask CTCL in some patients. Second, the manufacturer failed to warn patients and physicians about that risk, so diagnoses arrived later than they should have. The masking idea is the distinctive part: by suppressing skin inflammation, the drug may quiet the visible signs of an underlying cancer, delaying a biopsy until the disease has advanced. Sanofi and Regeneron dispute the causal claim, arguing the scientific literature does not support a causal association — and that dispute is why the expert-evidence phase, not opening statements, will matter most.
What the FDA Signal Does — and Does Not — Prove
The U.S. Food and Drug Administration, the agency that approves drugs and monitors their safety after approval, listed CTCL as a potential signal of serious risk for Dupixent in its October to December 2024 quarterly report, with the table current as of August 2026. A potential safety signal is the agency's term for a pattern in adverse-event reports that crosses a threshold worth reviewing. It is not a recall, not a warning letter, and not a label change. The agency has said it is evaluating whether regulatory action is needed.
That careful language is routinely overstated, so it deserves emphasis. A signal means the FDA saw enough case reports to look closer; it does not mean the FDA concluded the drug causes the disease. The reporting system behind it, called FAERS, collects reports from doctors, patients, and manufacturers that vary in quality. As of October 2025 it contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL-specific cases, according to summaries of the data. Those counts describe reports, not proven cases, and cannot by themselves establish how common the outcome is. The label question sits at the center of the claim: a failure-to-warn claim is a claim that a manufacturer did not give adequate warning about a known or knowable risk, and the current U.S. label's Warnings and Precautions section does not mention lymphoma.
What the Science Says So Far
The published research most often cited by plaintiffs is a 2024 study in the Journal of the American Academy of Dermatology, which analyzed 19,612 atopic dermatitis patients and reported that Dupixent users showed 4.1 times higher odds of developing CTCL than non-users, with a 95 percent confidence interval of 2.1 to 8.2, and that most diagnoses occurred more than one year after starting the drug. An odds ratio compares the odds of an outcome in one group with the odds in another; it is not the same as saying 4.1 times as many patients overall developed the disease, because CTCL is rare in both groups.
Other studies point in the same direction without settling the question. A 2024 TriNetX study of 1.18 million atopic dermatitis patients reported a 4.6 times higher relative risk, highest in patients over 60 and within the first year of treatment, and a 2025 analysis of FDA reports described a markedly higher CTCL reporting rate for Dupixent than for other medications. None is a randomized trial, and observational studies can be confounded: patients prescribed a powerful drug may differ from other patients in ways that also affect cancer risk, and early CTCL may be misdiagnosed as eczema before treatment begins, making the drug look like the cause of a cancer already present. That is why the plaintiffs phrase their claim in three verbs — cause, accelerate, or unmask — and why the answer may differ from patient to patient.
Where MDL 3180 Goes Next
The litigation is at an early stage. No trial dates have been set, and Sanofi and Regeneron have not announced any settlements. The panel left one scope question open: the cases so far involve CTCL, including mycosis fungoides and Sézary syndrome, while plaintiffs' lawyers have argued that peripheral T-cell lymphoma and other T-cell lymphomas belong in the litigation too, and that question may be resolved as additional cases arrive through the conditional-transfer process.
For patients, the practical timeline is measured in years, not weeks. After organization comes discovery, then expert challenges, then, if the court allows the cases forward, bellwether trials. A bellwether trial is a representative case tried first so both sides can gauge how juries respond; its result does not decide any other patient's case. The most useful step now is preserving the record: prescription history, dates of Dupixent use, dermatology notes describing how the rash changed, biopsy reports, and pathology results. Our guide to the Dupixent lawsuit explains the background and who has filed so far, our explainer on how an MDL works describes the stages before any trial, and our guide to FDA warnings in drug lawsuits shows how label language becomes evidence.
Who Benefits From This — and Who Does Not
People diagnosed with CTCL, mycosis fungoides, or Sézary syndrome after using Dupixent benefit most from following this litigation, because the MDL is where their shared causation questions will be tested and filing deadlines tracked. People whose rash changed character during treatment — spreading, thickening, or resisting treatment that once worked — benefit from asking their doctor whether a skin biopsy is appropriate, since early CTCL is far more treatable than late CTCL. Families of patients already diagnosed benefit from preserving records now, while clinics still hold them.
People who used Dupixent without any skin-cancer diagnosis do not benefit from joining this litigation, because there is no claim without a diagnosis, and worry alone is not a case. People whose only diagnosis is a different cancer should not assume this MDL covers them, since the scope question for other T-cell lymphomas is still open. And anyone who stops Dupixent on the basis of a news article, without talking to their prescriber, risks losing control of the eczema or asthma the drug was treating.
Frequently Asked Questions
Who benefits most from following the Dupixent MDL?
People diagnosed with CTCL, mycosis fungoides, or Sézary syndrome after using Dupixent benefit most, because the MDL is where their shared causation questions will be tested.
Who does not benefit, or is not eligible, in this litigation?
People who used Dupixent without a skin-cancer diagnosis do not have a claim in this MDL, and people with a different cancer should not assume coverage, since the scope for other T-cell lymphomas is still open.
How do I start if I was diagnosed after using Dupixent?
Do not stop any prescribed medication without talking to your doctor. Gather your prescription history, dermatology notes, biopsy reports, and pathology results, and have a lawyer review the file promptly, because each state has its own filing deadline.
Has Dupixent been recalled over CTCL?
No. The FDA listed CTCL as a potential safety signal and is evaluating whether regulatory action is needed, but it has not issued a recall and the U.S. label still carries no lymphoma warning.
Has the Dupixent label been changed to warn about lymphoma?
Not in the United States. The current label's Warnings and Precautions section does not mention lymphoma, and that omission is central to the plaintiffs' failure-to-warn claim.
What happens next in MDL 3180?
Discovery and expert evidence come first, and the court must decide whether each side's causation experts may testify before any bellwether trial is set. No trial dates have been set and no settlement has been announced.
This article provides general information only and is not legal or medical advice. Do not stop taking a prescribed medication without talking to your doctor. Filing deadlines, label rules, and claim requirements vary, so consult a licensed attorney in your state about your specific situation.